MaxCyte, Inc. (MXCT) Net margin 2019–2025
MaxCyte, Inc. (MXCT) net profit margin by fiscal year — reported net income divided by reported revenue.
-213.0%FY2025 · since FY2019: -97.3% → -213.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -213.0% | -28.2 pp |
| FY2024 | -184.8% | +9.7 pp |
| FY2023 | -194.5% | -112.5 pp |
| FY2022 | -82.0% | +6.5 pp |
| FY2021 | -88.5% | -12.0 pp |
| FY2020 | -76.5% | +20.8 pp |
| FY2019 | -97.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More MXCT financial trends
MXCT RevenueMXCT Net incomeMXCT Gross profitMXCT Gross marginMXCT Operating incomeMXCT Operating marginMXCT Operating cash flowMXCT Free cash flowMXCT Capital expendituresMXCT Return on equityMXCT Stock buybacksMXCT Dividends paidMXCT Total assetsMXCT Total liabilitiesMXCT Shareholders’ equityMXCT overview →